Covers R&D, quality control, and production stages, eliminating incompatibility between inspection equipment and data silos across different phases, ensuring continuity and consistency of quality management.
A single device integrates triple inspection functions, avoiding the procurement, floor space occupation, and maintenance costs of multiple systems. Multi-scenario adaptation is achieved without equipment switching, reducing setup and training costs.
Non-destructive and non-invasive inspection prevents loss of high-value biologics and innovative drug samples, reducing experimental and production losses.
End-to-end quality control capabilities meet stringent compliance requirements in pharmaceutical and biopharmaceutical industries, supporting enterprises in achieving relevant certifications.